Loading...
THRX logo

Theseus Pharmaceuticals, Inc.NasdaqGS:THRX Stock Report

Market Cap US$180.7m
Share Price
n/a
My Fair Value
n/a
1Y-63.4%
7D-0.5%
1D
Portfolio Value
​
View

Theseus Pharmaceuticals, Inc.

NasdaqGS:THRX Stock Report

Market Cap: US$180.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Theseus Pharmaceuticals (THRX) Stock Overview

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. More details

THRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 6.3% per year for the next 3 years

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


THRX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Theseus Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Theseus Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.06
52 Week HighUS$12.37
52 Week LowUS$2.05
Beta3.98
1 Month Change0.74%
3 Month Change18.37%
1 Year Change-63.42%
3 Year Changen/a
5 Year Changen/a
Change since IPO-78.15%

Recent News & Updates

Seeking Alpha • Feb 01

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Summary Theseus Pharmaceuticals is being acquired by Concentra Biosciences at a cash price of $4.05 per share. Shareholders will also receive a contingent value right that includes 80% of the net proceeds from any license or disposition of Theseus programs. The CVR also includes potential cost savings that could result in an additional $0.04 per share for shareholders. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Feb 01

Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR

Summary Theseus Pharmaceuticals is being acquired by Concentra Biosciences at a cash price of $4.05 per share. Shareholders will also receive a contingent value right that includes 80% of the net proceeds from any license or disposition of Theseus programs. The CVR also includes potential cost savings that could result in an additional $0.04 per share for shareholders. Read the full article on Seeking Alpha
Analysis Article • Aug 18

Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • May 05

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 07

Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line

Theseus Pharmaceuticals press release (NASDAQ:THRX): Q2 GAAP EPS of -$0.30 in-line. Cash and cash equivalents and short-term and long-term investments of $228.6 million.
Analysis Article • Apr 22

Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

THRXUS PharmaceuticalsUS Market
7D-0.5%2.7%-2.4%
1Y-63.4%38.2%21.5%

Return vs Industry: THRX underperformed the US Pharmaceuticals industry which returned 16.8% over the past year.

Return vs Market: THRX underperformed the US Market which returned 16.6% over the past year.

Price Volatility

Is THRX's price volatile compared to industry and market?
THRX volatility
THRX Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: THRX's share price has been volatile over the past 3 months.

Volatility Over Time: THRX's weekly volatility has decreased from 16% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201738n/atheseusrx.com

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.

Theseus Pharmaceuticals, Inc. Fundamentals Summary

How do Theseus Pharmaceuticals's earnings and revenue compare to its market cap?
THRX fundamental statistics
Market capUS$180.72m
Earnings (TTM)-US$56.61m
Revenue (TTM)n/a
0.0x
P/S Ratio
-3.2x
P/E Ratio

Is THRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
THRX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$56.61m
Earnings-US$56.61m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.27
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did THRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/14 09:56
End of Day Share Price 2024/02/14 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Theseus Pharmaceuticals, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alethia YoungCantor Fitzgerald & Co.
Andrew FeinH.C. Wainwright & Co.
Maurice RaycroftJefferies LLC